Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.24, $0.01 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $87.9 million versus the consensus estimate of $87.67 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.